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Tumor cell metastasis to distant organs is an inefficient process that is limited in part by recently identified metastasis sup-
pressors. Interactions between tumor cells and the surrounding stroma are thought to control much of cancer progression. In 
the August issue of Nature Medicine, Bandyopadhyay et al. (2006) demonstrate that specific cell surface interactions between 
the metastasis suppressor KAI1 on tumor cells and the decoy cytokine receptor DARC on adjacent vascular cells triggers 
senescence in the tumor cells and suppresses metastasis. These new observations demonstrate how metastasis suppressors 
can relay the restraint imposed by the stroma onto disseminating tumor cells.It has become apparent that tumor cell 
metastasis is controlled by molecular 
processes distinct from those that control 
tumorigenesis. Progression of metasta-
sis appears to be controlled in part by 
a unique subset of genes that suppress 
tumor cell dissemination without affecting 
development of the primary tumor (Rinker-
Schaeffer et al., 2006). While increasing 
numbers of metastasis suppressor genes 
are being identified, they are primarily 
operationally defined and rarely mecha-
nistically understood. It should come 
as no surprise that, like tumorigenesis, 
metastasis is strongly influenced by inter-
actions between the tumor and stromal 
cells. Recent work suggests that paracrine 
CSF-1 and EGF signaling makes macro-
phages obligate partners in early steps in 
metastasis (Condeelis and Pollard, 2006), 
and that hematopoietic progenitors gen-
erate a metastatic niche through SDF-1- 
and CXCR-4-mediated communication 
with metastasizing tumor cells (Kaplan et 
al., 2005). Continuous interaction between 
the tumor and host cells occurs in a tis-
sue-specific manner, and metastasis 
suppressors could regulate each of the 
rate-limiting steps of the metastatic cas-
cade. While some of these interactions 
occur via soluble ligands, others occur 
through transmembrane proteins proximal 
to the cellular surface. Among the latter, 
the tetraspanins KAI1/CD82 and PETA-
3/CD151 have both been demonstrated 
to regulate metastasis (Hemler, 2005). 
However, all of their interacting partners 
have, up to now, been defined as adjacent 
transmembrane or proximal cytoplasmic 
proteins expressed within the tumor cell 
itself. For the first time, researchers in the 
Watabe lab (Bandyopadhyay et al., 2006) 
demonstrate that vascular cells can limit 
tumor cell proliferation and induce senes-
cence by molecular handshaking between 
the metastasis suppressor KAI1/CD82 on 
metastasizing tumor cells and the cyto-
kine decoy receptor DARC (Duffy antigen 
cancer cell september 2006 receptor for cytokines) on the encountered 
or adjacent vascular cells.
KAI1/CD82 is a member of the tet-
raspanin family, which consists of 32 mem-
bers that play critical roles in a myriad of 
biological processes ranging from sperm-
egg fusion to retinal integrity to metastasis. 
The tetraspanins are functionally defined 
as organizers of web-like multimolecular 
Figure 1. Direct interaction between KAI1-express-
ing tumor cells and DArC-expressing endothelial 
cells limits proliferation of metastasizing cells
KAI1-positive (green) and -negative (blue) tumor 
cells disseminating from the primary tumor are 
exposed to the vascular cells while intravasat-
ing at the primary site as well as during arrest 
and extravasation at the secondary site. In the 
absence of DArC (DArC−/−), both KAI1-positive 
and -negative cells proliferate in the circula-
tion and metastasize. In the presence of DArC 
(DArC+/+), handshaking between cell surface 
KAI1 and DArC on adjacent tumor (tC) and 
endothelial cells (eC) inhibits proliferation of KAI1-
positive tumor cells (green) in the vasculature by 
inducing senescence (enlarged view). As a con-
sequence, only KAI1-negative cells (blue) prolifer-
ate in DArC-expressing vasculature.membrane complexes and interact with 
numerous membrane proteins, including 
integrins, growth factor receptors, and 
other tetraspanins. However, there is little 
mechanistic understanding of tetraspanin 
function (Hemler, 2005). Consequently, 
although KAI1/CD82 was identified as a 
metastasis suppressor more than 10 years 
ago (Dong et al., 1995), a definitive mecha-
nism of action of the suppression has not 
been forthcoming.
Using yeast two-hybrid screening, 
Bandyopadhyay et al. (2006) surprisingly 
identified the seven transmembrane pro-
tein DARC as a specific KAI1 interacting 
partner. DARC has been well established 
as a cytokine decoy receptor with specific 
ligand interactions and has an accepted 
role in sequestering soluble cytokines 
from functionally endowed receptors (Rot, 
2005). Interestingly, DARC expression is 
limited to select cell types, including endo-
thelial cells, erythrocytes, and a few spe-
cific epithelial cells. Bandyopadhyay et al. 
(2006) nicely demonstrate that direct inter-
action between KAI1-expressing prostate 
tumor cells and DARC-expressing endo-
thelial cells leads to suppression of prolif-
eration and the induction of senescence in 
the KAI1-expressing cells. Direct contact 
between KAI1 and DARC was indicated by 
coimmunoprecipitation of the KAI1-DARC 
complex in crosslinking experiments and 
inhibition of adhesion between KAI1- 
and DARC-expressing cells using anti-
KAI1 antibodies. Yet the most compelling 
results in this study were from a series of 
spontaneous and experimental metasta-
sis experiments using metastatic variants 
of the syngeneic B16 melanoma cell line 
in wild-type and Darc−/− mice. Tumor cells 
that lacked KAI1 expression metastasized 
equally well in wild-type and Darc−/− mice. 
However, tumor cell KAI1 expression dra-
matically suppressed spontaneous and 
experimental metastasis in wild-type but 
not Darc−/− mice. KAI1 expression does 
not lead to reduced primary tumor size, 177
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tact between KAI1-positive tumor cells and 
DARC-positive vascular cells. The metas-
tasis-specific senescence appears to be 
due to KAI1-DARC interactions occurring 
between tumor cells and vascular cells 
during transit of the tumor cells in circula-
tion (Figure 1). The study demonstrates 
that direct physical contact between stromal 
cells and “in transit” tumor cells can control 
the survival of the disseminating metastatic 
cells—a phenomenon quite distinct from 
microenvironmental influences at the site 
of the primary tumor.
Although DARC is a promiscuous 
cytokine receptor, Darc−/− mice exhibit no 
detectable phenotype deficiency except for 
a moderate delay in inflammatory cell influx, 
possibly suggesting DARC involvement in 
endothelial interactions with another “cell in 
transit.” DARC is also the erythrocyte recep-
tor for the malarial parasite, and it is inter-
esting that, among the human population, 
70% of individuals of West African descent 
lack DARC erythrocyte expression and are 
resistant to malaria infection. However, men 
of African descent are not known to exhibit 
decreased immune function but do exhibit 
a 60% greater incidence of prostate cancer 
and a corresponding 2-fold greater mortal-
ity (Luo et al., 2000), possibly suggesting a 
deficient suppressor function. Wang et al. 
(2006) also demonstrated independently 
that DARC can act as a negative regulator 
of metastasis. Upon transfection of meta-
static breast cancer cells with DARC, they 
observed diminished metastasis thought to 
be due to decreased angiogenesis, which 
limited tumor size. This correlation is bol-
stered by clinical evidence from the same 
study that links low expression of DARC with 
poor patient survival and metastasis. Could 
it be possible in these cases that a reversal 
of roles occurs, and DARC expression on 178 tumor cells limits the proliferation of KAI1-
positive angiogenic endothelial cells?
Because KAI1 and DARC have both 
been clinically demonstrated to be negative-
ly correlated with metastasis and disease 
progression, it is rewarding to now witness 
a possible mechanistic connection between 
these two suppressor genes. However, 
the structural/biochemical evidence of 
their physical interaction remains limited. 
Because of its incorporation into larger 
molecular complexes of the tetraspanin 
enriched microdomains (Hemler, 2005), 
KAI1 is unlikely to act as an isolated player, 
thus leaving for future investigation the iden-
tification of the functional KAI1 membrane 
complex that interacts with DARC. The 
results from the study by Bandyopadhyay 
et al. (2006), although not definitive in terms 
of the biochemistry of KAI1-DARC interac-
tion, do indeed represent the first indication 
that the tumor suppressor KAI1 engages a 
specific and distinct interaction with DARC-
expressing vascular cells and initiates a 
suppression of proliferation of tumor cells 
“in transit” to a metastatic site.
While it is tempting to assume that sup-
pression of proliferation in the vasculature 
would limit metastasis, nonproliferative cells 
might still be capable of escaping the vas-
culature and subsequently proliferating in 
the DARC-negative stroma. This suggests 
that intravascular proliferation of metasta-
sizing cells (Al-Mehdi et al., 2000) may be 
more critical than previously thought, or that 
additional KAI1 suppressive mechanism(s) 
control invasion/expansion of metastatic 
cells within the stroma of the secondary site 
(Sridhar and Miranti, 2006).
Hence, until the operational impor-
tance of this tetraspanin-DARC interaction 
in metastasis becomes mechanistically 
defined, it remains molecularly complex and 
location obscure.Andries Zijlstra1  
and James p. Quigley2,*
1Department of pathology, Vanderbilt 
University, Nashville, tennessee 37232 
2Department of Cell biology, the scripps 
research Institute, La Jolla, California 92037 
*e-mail: jquigley@scripps.edu
Selected reading
Al-Mehdi, A.B., Tozawa, K., Fisher, A.B., Shientag, 
L., Lee, A., and Muschel, R.J. (2000). Nat. Med. 
6, 100–102.
Bandyopadhyay, S., Zhan, R., Chaudhuri, A., 
Watabe, M., Pai, S.K., Hirota, S., Hosobe, S., 
Tsukada, T., Miura, K., Takano, Y., et al. (2006). 
Nat. Med. 12, 933–938.
Condeelis, J., and Pollard, J.W. (2006). Cell 124, 
263–266.
Dong, J.T., Lamb, P.W., Rinker-Schaeffer, C.W., 
Vukanovic, J., Ichikawa, T., Isaacs, J.T., and 
Barrett, J.C. (1995). Science 268, 884–886.
Hemler, M.E. (2005). Nat. Rev. Mol. Cell Biol. 6, 
801–811.
Kaplan, R.N., Riba, R.D., Zacharoulis, S., Bramley, 
A.H., Vincent, L., Costa, C., MacDonald, D.D., Jin, 
D.K., Shido, K., Kerns, S.A., et al. (2005). Nature 
438, 820–827.
Luo, H., Chaudhuri, A., Zbrzezna, V., He, Y., and 
Pogo, A.O. (2000). Mol. Cell. Biol. 20, 3097–
3101.
Rinker-Schaeffer, C.W., O’Keefe, J.P., Welch, D.R., 
and Theodorescu, D. (2006). Clin. Cancer Res. 12, 
3882–3889.
Rot, A. (2005). Cytokine Growth Factor Rev. 16, 
687–694.
Sridhar, S.C., and Miranti, C.K. (2006). Oncogene 
25, 2367–2378.
Wang, J., Ou, Z.L., Hou, Y.F., Luo, J.M., Shen, 
Z.Z., Ding, J., and Shao, Z.M. (2006). Oncogene. 
Published online June 19, 2006. 10.1038/
sj.onc.1209703.
DOI 10.1016/j.ccr.2006.08.012cancer cell september 2006
